Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.

Jakubowiak A.

Semin Hematol. 2012 Jul;49 Suppl 1:S16-32. doi: 10.1053/j.seminhematol.2012.05.003. Review.

PMID:
22727389
2.

The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.

Moreau P.

Semin Hematol. 2012 Jul;49 Suppl 1:S33-46. doi: 10.1053/j.seminhematol.2012.05.004.

PMID:
22727391
3.

Choosing treatment options for patients with relapsed/refractory multiple myeloma.

Castelli R, Orofino N, Losurdo A, Gualtierotti R, Cugno M.

Expert Rev Anticancer Ther. 2014 Feb;14(2):199-215. doi: 10.1586/14737140.2014.863153. Epub 2013 Dec 13. Review.

PMID:
24329153
4.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
5.

Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A.

Cancer Treat Rev. 2011 Jun;37(4):266-83. doi: 10.1016/j.ctrv.2010.08.008. Epub 2010 Sep 21. Review.

PMID:
20863623
6.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
7.

Management of relapsed and relapsed/refractory multiple myeloma.

Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG.

J Natl Compr Canc Netw. 2011 Oct;9(10):1209-16.

PMID:
21975917
8.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
9.

Treatment of relapsed/refractory multiple myeloma.

Kastritis E, Palumbo A, Dimopoulos MA.

Semin Hematol. 2009 Apr;46(2):143-57. doi: 10.1053/j.seminhematol.2009.01.004. Review.

PMID:
19389498
10.

Management of multiple myeloma with bortezomib: experts review the data and debate the issues.

Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P.

Oncology. 2006;70(6):474-82. Epub 2007 Feb 2. Review.

PMID:
17283449
11.

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M.

Leukemia. 2012 Jan;26(1):73-85. doi: 10.1038/leu.2011.310. Epub 2011 Oct 25. Review.

PMID:
22024721
12.

Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.

Siegel DS.

Semin Hematol. 2012 Jul;49 Suppl 1:S3-15. doi: 10.1053/j.seminhematol.2012.05.005.

PMID:
22727390
13.

Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.

Siegel DS, Vij R, Jakubowiak AJ.

Clin Adv Hematol Oncol. 2011 Apr;9(4):1-15.

PMID:
21928467
14.

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.

Richardson P, Jagannath S, Colson K.

Clin Adv Hematol Oncol. 2006 May;4(5):1; discussion 8; suppl 13.

PMID:
16830422
15.

Advances in treatment for relapses and refractory multiple myeloma.

Richards T, Weber D.

Med Oncol. 2010 Jun;27 Suppl 1:S25-42. doi: 10.1007/s12032-009-9407-5. Epub 2010 Mar 6. Review.

PMID:
20213220
16.

New drugs for myeloma.

Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.

Oncologist. 2007 Jun;12(6):664-89. Review.

17.

Lenalidomide in multiple myeloma.

Richardson PG, Mitsiades C, Hideshima T, Anderson KC.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1165-73. Review.

PMID:
16925483
18.

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.

Raje N, Hideshima T, Anderson KC.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1239-47. Review.

PMID:
17020458
19.

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.

Jagannath S, Dimopoulos MA, Lonial S.

Leuk Res. 2010 Sep;34(9):1111-8. doi: 10.1016/j.leukres.2010.04.001. Epub 2010 May 15. Review.

PMID:
20472288
20.

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.

van de Donk NW, Lokhorst HM.

Expert Opin Pharmacother. 2013 Aug;14(12):1569-73. doi: 10.1517/14656566.2013.805746. Epub 2013 May 31.

PMID:
23721099

Supplemental Content

Support Center